Home / CMS Lawyers in Austria / Gabriela Staber
Portrait ofGabriela Staber

Gabriela Staber

Partner

CMS Reich-Rohrwig Hainz
Rechtsanwälte GmbH
Gauermanngasse 2
1010 Vienna
Austria
Languages German, English
Intellectual Property

Gabriela Staber is an attorney-at-law specialising in Intellectual Property and Unfair Competition Law with a sector focus on Life Sciences & Healthcare and TMC - Technology, Media & Telecommunications.

In addition to dispute resolution, her expertise includes the criminal prosecution of infringements, the licensing of intellectual property rights, the negotiation of cross-border and international agreements, the protection of designs, know-how and trade secrets, the management of trademark portfolios, service invention law, software law, advertising and product labelling as well as antitrust issues related to intellectual property rights.
Staber regularly gives lectures and training courses in the above-mentioned specialist areas. She regularly publishes in specialist journals and has co-authored commentaries on the EU Trade Mark Regulation and the Community Design Regulation.

more less

"Gabriela Staber is always solution-oriented and provides excellent client service and expertise."

Chambers Europe, 2024

"Gabriela Staber makes complex issues easy to understand and always exceeds expectations."

WTR1000, 2024

"We had great cooperation with Gabriela, who was responsive and gave clear advice showing a good understanding of our priorities."

Chambers Europe, 2023

"Gabriela Staber stands out."

The Legal 500, 2023

"She is right up there as a pharmaceutical specialist."

Chambers Europe, 2023

Memberships & Roles

  • International Trademark Association (INTA)
  • Pharmaceutical Trade Marks Group (PTMG)
  • Austrian Bar Association
more less

Awards & Rankings

  • Gabriela continuously achieves the highest ranks for her notable skills such as Tier 1 by Chambers Europe and has been recommended by JUVE, World Trademark Review (WTR) and Legal 500 as an expert that “stands out” for several years in a row.
more less

Publications

  • Fälschungsschutz versus Markenrechte – Wann ist das Umpacken, Rebranding und Debranding von Arzneimitteln erlaubt?, JMG 2023, 152.
  • Patientenunterstützungsprogramme – Förderung der Therapietreue oder unzulässige Arzneimittelwerbung, JMG 2022, 231.
  • Impfschadengesetz: Verschuldensunabhängige Entschädigung für Schäden durch eine COVID-19 Impfung, JMG 2022, 126.
  • Scharf/Staber, Private Enforcement von Datenschutzverstößen – noch immer alles offen?, ecolex 2022, 153.
  • Mahfoozpour/Staber, Spannungsfeld „Greenwashing“: Eine Rechtsprechungsübersicht, NR 2022, 62.
  • Gilt die Konformitätsvermutung für Medizinprodukte auch im UWG-Prozess?, RdM 2021/112.
  • Glosse zu OGH 22.9.2020, 4 Ob 135/20m, ecolex 2021/113.
  • Scharf/Staber, Update zur lauterkeitsrechtlichen Verfolgbarkeit von Datenschutzverstößen, ecolex 2020, 909.
  • Scharf/Staber, Data Protection vs Unfair Competition Law: Round 1, CMS Law-Now, 25.2.2020.
  • Staber/Scharf, Datenschutz vs. Wettbewerbsrecht: Runde 1, NetV 2/2020, 56.
  • Scharf/Staber, Abmahnungen wegen Verstößen gegen die DSGVO - Die Ruhe vor dem Sturm?, ecolex 9/2019, 787.
  • Staber in Hasselblatt (Hrsg.), European Union Trademark Regulation2 Art. 111–118 (Beck, Hart, Nomos 2018).
  • Staber in Hasselblatt (Hrsg.), Community Design Regulation Art. 55–58 (Beck, Hart, Nomos 2018).
  • Staber/Engin-Deniz/Kaindl, Distribution and Marketing of Drugs in Austria, Country Q&A (Thomson Reuters 2018). 
more less

Education

  • 2011 - Admitted to practice law in New York and Massachusetts
  • 2010 - LL.M., Intellectual Property and Information Technology Law & U.S. Law, Suffolk Law School, Boston
  • 2007 - Admitted to the Austrian Bar
  • 2004 - Dr.in iur., Corporate Law (Antitrust Law), University of Vienna
  • 2001 - LL.M., European Law, King's College London
  • 1999 - Mag.a iur., Law, University of Vienna
more less
Life Sciences & Healthcare

Gabriela Staber is an attorney-at-law specialising in Intellectual Property and Unfair Competition Law with a sector focus on Life Sciences & Healthcare and TMC - Technology, Media & Telecommunications.

She advises on issues related to the marketing and distribution of pharmaceuticals and medical devices as well as the protection of intellectual property. Her expertise includes advertising and product labelling, compliance, restructuring of distribution systems, reimbursement / market access, clinical trials, licensing, anti-counterfeiting and parallel import measures and dispute resolution. Her clients include pharmaceutical, medical device and biotechnology companies, healthcare start-ups and online pharmacies.

more less

"Gabriela Staber is always solution-oriented and provides excellent client service and expertise."

Chambers Europe, 2024

"Gabriela Staber makes complex issues easy to understand and always exceeds expectations."

WTR1000, 2024

"We had great cooperation with Gabriela, who was responsive and gave clear advice showing a good understanding of our priorities."

Chambers Europe, 2023

"Gabriela Staber stands out."

The Legal 500, 2023

Memberships & Roles

  • International Trademark Association (INTA)
  • Pharmaceutical Trade Marks Group (PTMG)
  • Austrian Bar Association
more less

Awards & Rankings

  • Gabriela continuously achieves the highest ranks for her notable skills such as Tier 1 by Chambers Europe and has been recommended by JUVE, World Trademark Review (WTR) and Legal 500 as an expert that “stands out” for several years in a row.
more less

Publications

  • Fälschungsschutz versus Markenrechte – Wann ist das Umpacken, Rebranding und Debranding von Arzneimitteln erlaubt?, JMG 2023, 152.
  • Patientenunterstützungsprogramme – Förderung der Therapietreue oder unzulässige Arzneimittelwerbung, JMG 2022, 231.
  • Impfschadengesetz: Verschuldensunabhängige Entschädigung für Schäden durch eine COVID-19 Impfung, JMG 2022, 126.
  • Scharf/Staber, Private Enforcement von Datenschutzverstößen – noch immer alles offen?, ecolex 2022, 153.
  • Mahfoozpour/Staber, Spannungsfeld „Greenwashing“: Eine Rechtsprechungsübersicht, NR 2022, 62.
  • Gilt die Konformitätsvermutung für Medizinprodukte auch im UWG-Prozess?, RdM 2021/112.
  • Glosse zu OGH 22.9.2020, 4 Ob 135/20m, ecolex 2021/113.
  • Scharf/Staber, Update zur lauterkeitsrechtlichen Verfolgbarkeit von Datenschutzverstößen, ecolex 2020, 909.
  • Scharf/Staber, Data Protection vs Unfair Competition Law: Round 1, CMS Law-Now, 25.2.2020.
  • Staber/Scharf, Datenschutz vs. Wettbewerbsrecht: Runde 1, NetV 2/2020, 56.
  • Scharf/Staber, Abmahnungen wegen Verstößen gegen die DSGVO - Die Ruhe vor dem Sturm?, ecolex 9/2019, 787.
  • Staber in Hasselblatt (Hrsg.), European Union Trademark Regulation2 Art. 111–118 (Beck, Hart, Nomos 2018).
  • Staber in Hasselblatt (Hrsg.), Community Design Regulation Art. 55–58 (Beck, Hart, Nomos 2018).
  • Staber/Engin-Deniz/KaindlDistribution and Marketing of Drugs in Austria, Country Q&A (Thomson Reuters 2018). 
more less

Education

  • 2011 - Admitted to practice law in New York and Massachusetts
  • 2010 - LL.M., Intellectual Property and Information Technology Law & U.S. Law, Suffolk Law School, Boston
  • 2007 - Admitted to the Austrian Bar
  • 2004 - Dr.in iur., Corporate Law (Antitrust Law), University of Vienna
  • 2001 - LL.M., European Law, King's College London
  • 1999 - Mag.a iur., Law, University of Vienna
more less
TMC - Technology, Media & Communications

Gabriela Staber is an attorney-at-law specialising in intellectual property and unfair competition law with a sector focus on life sciences & healthcare and TMC (technology, media & telecommunications).  Her practice areas include television, telecommunications, new media and sports. Her expertise comprises the marketing of media rights, short reports, regulatory broadcasting and telecommunications law, advertising, licensing, copyright protection of media content, trademark law, protection of personal rights as well as reputation management and litigation and proceedings before regulatory authorities in these areas.

Gabriela Staber is an attorney-at-law specialising in Intellectual Property and Competition Law with a focus on the Life Sciences & Healthcare and TMC - Technology, Media & Telecommunications sectors. She advises on television, telecommunications, new media and sports, among other areas. Her expertise includes media rights marketing, short news reporting, regulatory broadcasting and telecommunications law, advertising, licensing, copyright protection of media content, trademark law, protection of personality rights, reputation management and litigation as well as proceedings before regulatory authorities in these areas.
Her clients include broadcasters, organisers of major sporting events, media companies and telecommunications companies.
 

more less

"Gabriela Staber is always solution-oriented and provides excellent client service and expertise."

Chambers Europe, 2024

"Gabriela Staber makes complex issues easy to understand and always exceeds expectations."

WTR1000, 2024

"We had great cooperation with Gabriela, who was responsive and gave clear advice showing a good understanding of our priorities."

Chambers Europe, 2023

"Gabriela Staber stands out."

The Legal 500, 2023

"She is right up there as a pharmaceutical specialist."

Chambers Europe, 2023

Memberships & Roles

  • International Trademark Association (INTA)
  • Pharmaceutical Trade Marks Group (PTMG)
  • Austrian Bar Association
more less

Awards & Rankings

  • Gabriela continuously achieves the highest ranks for her notable skills such as Tier 1 by Chambers Europe and has been recommended by JUVE, World Trademark Review (WTR) and Legal 500 as an expert that “stands out” for several years in a row.
more less

Publications

  • Fälschungsschutz versus Markenrechte – Wann ist das Umpacken, Rebranding und Debranding von Arzneimitteln erlaubt?, JMG 2023, 152.
  • Patientenunterstützungsprogramme – Förderung der Therapietreue oder unzulässige Arzneimittelwerbung, JMG 2022, 231.
  • Impfschadengesetz: Verschuldensunabhängige Entschädigung für Schäden durch eine COVID-19 Impfung, JMG 2022, 126.
  • Scharf/Staber, Private Enforcement von Datenschutzverstößen – noch immer alles offen?, ecolex 2022, 153.
  • Mahfoozpour/Staber, Spannungsfeld „Greenwashing“: Eine Rechtsprechungsübersicht, NR 2022, 62.
  • Gilt die Konformitätsvermutung für Medizinprodukte auch im UWG-Prozess?, RdM 2021/112.
  • Glosse zu OGH 22.9.2020, 4 Ob 135/20m, ecolex 2021/113.
  • Scharf/Staber, Update zur lauterkeitsrechtlichen Verfolgbarkeit von Datenschutzverstößen, ecolex 2020, 909.
  • Scharf/Staber, Data Protection vs Unfair Competition Law: Round 1, CMS Law-Now, 25.2.2020.
  • Staber/Scharf, Datenschutz vs. Wettbewerbsrecht: Runde 1, NetV 2/2020, 56.
  • Scharf/Staber, Abmahnungen wegen Verstößen gegen die DSGVO - Die Ruhe vor dem Sturm?, ecolex 9/2019, 787.
  • Staber in Hasselblatt (Hrsg.), European Union Trademark Regulation2 Art. 111–118 (Beck, Hart, Nomos 2018).
  • Staber in Hasselblatt (Hrsg.), Community Design Regulation Art. 55–58 (Beck, Hart, Nomos 2018).
  • Staber/Engin-Deniz/KaindlDistribution and Marketing of Drugs in Austria, Country Q&A (Thomson Reuters 2018). 
more less

Education

  • 2011 - Admitted to practice law in New York and Massachusetts
  • 2010 - LL.M., Intellectual Property and Information Technology Law & U.S. Law, Suffolk Law School, Boston
  • 2007 - Admitted to the Austrian Bar
  • 2004 - Dr.in iur., Corporate Law (Antitrust Law), University of Vienna
  • 2001 - LL.M., European Law, King's College London
  • 1999 - Mag.a iur., Law, University of Vienna
more less

Feed

15/04/2024
Green/sus­tain­ab­il­ity claims and advertising and consumer greenwashing
In the era of increased environmental awareness, the spotlight on green claims has never been more intense. As consumers are concerned about global heating and ecological sustainability, they are scrutinizing products like never before, seeking eco-friendly options that align with their values. In response, businesses have responded to this concern and consumers’ purchase interest, with brand-owners increasingly highlighting the benign or even beneficial effects their products and services have on the environment fostering a surge in green marketing initiatives. Yet, amidst this push for sustainability, the risk of being accused of greenwashing is omnipresent. As environmental characteristics of products and services are highly technical and the understanding of the various concepts involved is continuously changing, en­vir­on­ment­al/sus­tain­ab­il­ity claims raise a significant risk of confusing and misleading consumers. Many companies have fallen foul of advertising standards in this area recently. Given the high sensitivity of environmental claims and the reputational damage that can result from allegations of greenwashing, it is particularly important to make sure environmental claims are compliant. By ensuring truthful, accurate and unambiguous information is always given to the consumers, companies can avoid the risks and build a reputation for authenticity in their sustainability advertising and communications. CMS guides companies through the maze of regulations and case law and advise on the steps a company can take to ensure their advertising is not only compliant but also authentic and impactful. The priority questions we address are: Which green claims are likely to raise litigation or regulatory enforcement risks?What can businesses do to mitigate these risks?What are the likely claims/en­force­ment that could arise?Who is likely to make a claim?What are the risks in the event of a violation or a complaint? What future regulatory measures are expected and what companies have to do now to be prepared? We offer various solutions to help you be compliant and avoid accusations of greenwashing: Sustainability claim checks including regulatory risk matrix as well as litigation: evaluating the planned claims and mapping their risk as well as developing compliant marketing strategies and claims custom-tailored to your business's unique pro­file;Sus­tain­ab­il­ity-re­lated litigation: providing comprehensive support in legal disputes in the area of advertising with environmental claims;Training sessions: to empower your legal, compliance and sustainability as well as advertising teams with in-depth knowledge of sustainability risks and mitigation strategies; andBoard packs: to equip your directors/board members with actionable insights into greenwashing risks, ensuring they steer the company toward sustainable strategies with confidence and integrity.  For an initial conversation on how we can support you on greenwashing risk, please reach out to the lawyers listed on this page or to your usual CMS contact.
27/03/2024
Cannabis law and legislation in Austria
Medical use According to the Addictive Drugs Act, only the Austrian Agency for Health and Food Safety (AGES; supervised by the Austrian Federal Ministry of Labour, Social Affairs, Health and Consumer...
18/12/2023
Digital health apps and telemedicine in Austria
Digital Health Apps/Software 1. How is the software within digital health apps classified in your jurisdiction, and what regulation(s) apply? 1.1 Is it considered a “medical device” or a “product”...
Comparable
13/11/2023
Advertising with Green Claims and Sustainability Labels
CMS and Sustainability&
12/10/2023
CMS Reich-Rohrwig Hainz receives the Woman in Law Award 2023 for best Law...
12 October 2023 We are delighted to receive the Women in Law Award for Best Law Firm 2023, which confirms our ongoing commitment to diversity and equality in the legal industry. Our efforts to promote gender diversity, create a fair and inclusive working environment, and support initiatives such as the Ladies League have enriched our culture. Our CMS Diversity and Inclusion charter as well as our internal initiatives reflect our passion to promote women and diversity and to create an inclusive legal industry. We are grateful for this recognition and look forward to a future that is even more diverse, inclusive and sus­tain­able.    Spe­cial thanks to Future-Law, Women in Law Austria and the Association of Austrian Corporate Lawyers - VUJ for the award and to our Ladies League team: Denisa Brighton, Daniela Karollus-Bruner, Daniela Krömer, Jelena Nushol Fijačko, Andrea Potz, Maria Orlyk, Nedzida Sa­li­hovic-Whalen, Gabriela Staber, Marija Tesic and Döne Yalçın.
09/05/2023
Online gambling law and regulation in Austria
 Last updated: April 2023
23/03/2023
On the Pulse webinar series 2023 - Spring
Welcome to the launch of the On the Pulse webinar series
03/02/2023
Imminent decision on the legal standing of competitors in the case of data...
NewsMonitor | Data protection – Episode 6
29/11/2022
CMS Life Science Award 2022
Veröffentlicht am 29. November 2022In Kooperation mit CMS Reich-Rohrwig Hainz verlieh die Recht­swis­senschaft­liche Fakultät der Universität Innsbruck erstmals den „CMS Life Sciences Award“ 2022. Der diesjährige Preisträger Matthias Rief, Absolvent des Dokotratskolleg Medizinrecht und Gesundheitswesen an der Universität Innsbruck, wurde für seine Dissertation "Implantierbare Medizinprodukte der Klasse III: Ausgewählte Haftungsfragen vor dem Hintergrund der neuen Med­iz­in­produkte-Ver­or­d­nung (EU)" aus­gezeich­net. CMS Partnerin und Life Science & Healthcare Expertin Gabriele Staber vertrat CMS als Jurymitglied.
29/09/2022
Global Life Sciences & Healthcare Forum 2022
Uncertain times, an evolving legal framework: managing risks and ensuring social responsibility in the life sciences & healthcare sector
29/09/2022
Global LSHC Forum 2022
Uncertain times, an evolving legal framework: managing risks and ensuring social responsibility in the life sciences & healthcare sector
15/09/2022
Pharmaceutical advertising regulation and medical device advertising in...
1. Which laws are applicable regarding advertising of medicines and medical devices? 1.1 Medicines The primary legal source is the Medicinal Products Act (Ar­zneimit­tel­ge­setz – AMG). In addition, the...